Hematologic malignancies in the Japanese patients with inflammatory bowel disease

Journal of Gastroenterology

Volumn 49, Issue 9, 2014, Pages 1299-1306

  Fukata, Norimasa ^a   Okazaki, Kazuichi ^a   Omiya, Mika ^a   Matsushita, Mitsunobu ^a   Watanabe, Mamoru ^b   Tsubouchi, Hirohito ^c   Imai, Kozo ^d   Sasaki, Iwao ^e   Ueno, Fumiaki ^f   Fujiyama, Yoshihide ^g   Hirota, Yoshio ^h   Matsui, Toshiyuki ⁱ   Miura, Soichiro ^j   Hibi, Toshifumi ^k   Kohgo, Yutaka ^l   Suzuki, Yasuo ^m   Chiba, Tsutomu ⁿ   Ajioka, Yoichi ^o   Watanabe, Toshiaki ^p   Sugita, Akira ^q   Matsumoto, Takayuki ^r   Arimura, Yoshiaki ^s   Iijima, Hideki ^t   Iizuka, Bun Ei ^u   Iizuka, Masahiro ^v   Ikeuchi, Hiroki ^q   Ishiguro, Yoh ^w   Ishihara, Shunji ^x   Ito, Hiroaki ^y   Iwao, Yasushi ^k   Ohi, Hidehisa ^z   Okawa, Kiyotaka ^aa   Kato, Jun ^ab   Kameoka, Shingo ^u   Kinouchi, Yoshitaka ^ac   Kitano, Atsuo ^ad   Kinjo, Fukunori ^ae   Kusunoki, Masato ^af   Kudo, Shin Ei ^ag   Kobayashi, Kiyonori ^ah   Goto, Hidemi ^ai   Sasaki, Makoto ^aj   Saruta, Masayuki ^ak   Shimizu, Seiji ^al   Joh, Takashi ^am   Sugimura, Kazuhito ^an   Suzuki, Kenji ^o   Tanaka, Shinji ^ao   Dohi, Taeko ^ap   Naito, Yuji ^aq   Nakajima, Atsushi ^ar   Hatakeyama, Katsuyoshi ^o   Haruma, Ken ^as   Hirata, Ichiro ^at   Fujii, Hisao ^au   Futami, Kitaro ⁱ   Funayama, Yuji ^av   Mitsuyama, Keiichi ^aw   Motoya, Satoshi ^ax   Yoshioka, Kazuhiko ^ay   Yoden, Atsushi ^az   Watanabe, Kenji ^h   Asakura, Hitoshi ^ba   Muto, Tetsuichiro ^bb   Munakata, Akihiro ^bc   Katsuno, Tatsuro ^bd   Kagaya, Takashi ^be   Fukuda, Katsuyuki ^bf   Kunisaki, Reiko ^bg   Tajiri, Hitoshi ^bh   Ishige, Takashi ^bi   Yamamoto, Shojiro ^bj   more..

^a KANSAI MEDICAL UNIVERSITY   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c KAGOSHIMA UNIVERSITY   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f OFUNA CHUO HOSPITAL   (Japan)

^g SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^h OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ FUKUOKA UNIVERSITY   (Japan)

^j NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^k KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^l ASAHIKAWA MEDICAL COLLEGE   (Japan)

^m TOHO UNIVERSITY   (Japan)

ⁿ KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^o NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^p TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^q HYOGO COLLEGE OF MEDICINE   (Japan)

^r KYUSHU UNIVERSITY   (Japan)

^s SAPPORO MEDICAL UNIVERSITY   (Japan)

^t OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^u TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^v AKITA RED CROSS HOSPITAL   (Japan)

^w HIROSAKI UNIVERSITY   (Japan)

^x SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^y Infusion clinic   (Japan)

^z Imamura Hospital   (Japan)

^aa Osaka Juso Hospital   (Japan)

^ab OKAYAMA UNIVERSITY   (Japan)

^ac TOHOKU UNIVERSITY   (Japan)

^ad Wakakusa Daiichi Hospital   (Japan)

^ae UNIVERSITY HOSPITAL OF THE RYUKYUS   (Japan)

^af MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^ag SHOWA UNIVERSITY NORTHERN YOKOHAMA HOSPITAL   (Japan)

^ah KITASATO UNIVERSITY HOSPITAL   (Japan)

^ai NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^aj AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^ak JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^al WEST JAPAN RAILWAY COMPANY   (Japan)

^am NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^an NIIGATA CITY GENERAL HOSPITAL   (Japan)

^ao HIROSHIMA UNIVERSITY   (Japan)

^ap NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^aq KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^ar YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^as KAWASAKI MEDICAL SCHOOL   (Japan)

^at FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^au NARA MEDICAL UNIVERSITY   (Japan)

^av TOHOKU ROSAI HOSPITAL   (Japan)

^aw KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^ax Sapporo Kosei General Hospital   (Japan)

^ay KANSAI MEDICAL UNIVERSITY   (Japan)

^az OSAKA MEDICAL COLLEGE   (Japan)

^ba Koukann Clinic   (Japan)

^bb Cancer Institute Hospital   (Japan)

^bc HIROSAKI UNIVERSITY   (Japan)

^bd CHIBA UNIVERSITY   (Japan)

^be KANAZAWA UNIVERSITY   (Japan)

^bf ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^bg YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^bh OSAKA GENERAL MEDICAL CENTER   (Japan)

^bi GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^bj UNIVERSITY OF MIYAZAKI   (Japan)

more..

Author keywords

Crohn s disease; Hematologic malignancy; Inflammatory bowel disease; Lymphoproliferative disorder; Thiopurine; Ulcerative colitis

Indexed keywords

MERCAPTOPURINE; IMMUNOSUPPRESSIVE AGENT; PURINE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CHRONIC MYELOID LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; JAPANESE (PEOPLE); LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MARGINAL ZONE LYMPHOMA; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; QUESTIONNAIRE; ULCERATIVE COLITIS; WALDENSTROEM MACROGLOBULINEMIA; ADOLESCENT; AGED; CHILD; CLINICAL TRIAL; COLITIS, ULCERATIVE; HEMATOLOGIC NEOPLASMS; JAPAN; MIDDLE AGED; MULTICENTER STUDY; RETROSPECTIVE STUDY; RISK FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; COLITIS, ULCERATIVE; CROHN DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JAPAN; MALE; MIDDLE AGED; PURINES; QUESTIONNAIRES; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84927128488     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-013-0873-3     Document Type: Article

References (36)

1. Jones JL, Loftus EV Jr. Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment? Inflamm Bowel Dis. 2007;13:1299-307.
2. Ueno F, Matsui T, Matsumoto T, et al. Evidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in Japan. J Gastroenterol. 2013;48:31-72.
3. Hamilton MJ, Snapper SB, Blumberg RS. Update on biologic pathways in inflammatory bowel disease and their therapeutic relevance. J Gastroenterol. 2012;47:1-8.
4. Hoshida Y, Xu J-X, Fujita S, et al. Lymphoproliferative disorders in rheumatoid arthritis: clinic-pathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol. 2007;34:322-31.
5. Kondo S, Tanimoto K, Yamada K, et al. Mature T/NK-cell lymphoproliferative disease and Epstein-Barr virus infection are more frequent in patients with rheumatoid arthritis treated with methotrexate. Virchows Arch. 2013;462:399-407.
6. Ichikawa A, Arakawa F, Kiyasu J, et al. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol. 2013;91:20-8.
7. Sokol H, Beaugerie L. Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle. Gut. 2009;58:1427-36.
8. Ekbom A, Helmick C, Zack M, et al. Extracolonic malignancies in inflammatory bowel disease. Cancer. 1991;67:2015-9.
9. Persson PG, Karlen P, Bernell O, et al. Crohn's disease and cancer: a population-based cohort study. Gastroenterology. 1994;107:1675-9.
10. Karlen P, Lofberg R, Brostrom O, et al. Increased risk of cancer in ulcerative colitis: a population-based cohort study. Am J Gastroenterol. 1999;94:1047-52.
11. Loftus EV Jr, Tremaine WJ, Habermann TM, et al. Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol. 2000;95:2308-12.
12. Palli D, Trallori G, Bagnoli S, et al. Hodgkin's disease risk is increased in patients with ulcerative colitis. Gastroenterology. 2000;119:647-53.
13. Bernstein CN, Blanchard JF, Kliewer E, et al. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001;91:854-62.
14. Lewis JD, Bilker WB, Brensinger C, et al. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology. 2001;121:1080-7.
15. Winther KV, Jess T, Langholz E, et al. Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol. 2004;2:1088-95.
16. Jess T, Winther KV, Munkholm P, et al. Intestinal and extraintestinal cancer in Crohn's disease: follow-up of a populationbased cohort in Copenhagen County, Denmark. Aliment Pharmacol Ther. 2004;19:287-93.
17. Askling J, Brandt L, Lapidus A, et al. Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut. 2005;54:617-22.
18. von Roon AC, Reese G, Teare J, et al. The risk of cancer in patients with Crohn's disease. Dis Colon Rectum. 2007;50: 839-55.
19. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374:1617-25.
20. Vos AC, Bakkal N, Minnee RC, et al. Risk of malignant lymphoma in patients with inflammatory bowel diseases: a Dutch nationwide study. Inflamm Bowel Dis. 2011;17:1837-45.
21. Kinlen LJ. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med. 1985;78:44-9.
22. Connell WR, Kamm MA, Dickson M, et al. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet. 1994;343:1249-52.
23. Korelitz BI, Mirsky FJ, Fleisher MR, et al. Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine. Am J Gastroenterol. 1999;94:3248-53.
24. Farrell RJ, Ang Y, Kileen P, et al. Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut. 2000;47:514-9.
25. Fraser AG, Orchard TR, Robinson EM, et al. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment Pharmacol Ther. 2002;16:1225-32.
26. Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54:1121-5.
27. Glazier KD, Palance AL, Griffel LH, et al. The ten-year singlecenter experience with 6-mercaptopurine in the treatment of inflammatory bowel disease. J Clin Gastroenterol. 2005;39:21-6.
28. Yano Y, Matsui T, Hirai F, et al. Cancer risk in Japanese Crohn's disease patients: investigation of the standardized incidence ratio. J Gastroenterol Hepatol. 2013;28:1300-5.
29. Matsuda T, Marugame T, Kamo K, et al. Cancer Incidence and Incidence Rates in Japan in 2005: based on Data from 12 Population-based Cancer Registries in the Monitoring of Cancer Incidence in Japan (MCIJ) Project. Jpn J Clin Oncol. 2011;41: 139-47.
30. Matsuda T, Marugame T, Kamo K, et al. Cancer incidence and incidence rates in Japan in 2006: based on data from 15 population-based cancer registries in the monitoring of cancer incidence in Japan (MCIJ) project. Jpn J Clin Oncol. 2012;42: 139-47.
31. Pedersen N, Duricova D, Elkjaer M, et al. Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies. Am J Gastroenterol. 2010;105:1480-7.
32. Caspi O, Polliack A, Klar R, et al. The association of inflammatory bowel disease and leukemia-coincidence or not? Leuk Lymphoma. 1995;17:255-62.
33. Froilan Torres C, Castro Carbajo P, Pajares Villarroya R, et al. Acute spontaneous tumor lysis syndrome in a patient with Crohn's disease taking immunosuppressants. Rev Esp Enferm Dig. 2009;101:288-94.
34. Walker G, Venkatachalam P, Bird J, et al. Mixed fortunes in the treatment of Crohn's disease. Lancet. 2012;379:2212.
35. Mullier F, Rahier JF, Maignen F, et al. A case of therapy-related myeloid neoplasm in a patient with Crohn's disease treated with azathioprine. Acta Haematol. 2012;128:1-6.
36. Ochenrider MG, Patterson DJ, Aboulafia DM. Hepatosplenic T-Cell lymphoma in a young man with Crohn's disease: case report and literature review. Clin Lymphoma Myeloma Leuk. 2010;10:144-8.